Overview

Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase Ib/IIa study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Cartesian Therapeutics
Treatments:
Antibodies
Autoantibodies